








THERAPEUTIC AREA	DISCOVERY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PHASE 4 / REGULATORY	LCM
 Immunology	++	<b>PIDD: recIG (Plasma-derived Ig enriched with recombinant polyclonal antibodies)</b>  <i>PIDD: Primary immunodeficiency disorder Ig: Immunoglobulin</i>			<b>PIDD: IVIG-PEG</b>  <b>CLL: Xembify®</b>  <i>IVIG: Intravenous immunoglobulin CLL: Chronic lymphocytic leukemia</i>	<b>PIDD: Xembify® Europe</b> <b>PIDD: Xembify® Bi-weekly dose</b> <b>PIDD: Yimmugo® (IVIG-G Next Gen)</b> <small>Commercialization started</small>	<b>PIDD: Xembify® Prefilled syringes</b>
 Hepatology / Intensive Care	++				<b>DECOMPENSATED CIRRHOSIS: Albumin 20% (PRECIOSA trial)</b>  <b>ACUTE-ON-CHRONIC LIVER FAILURE: Albumin 5% (APACHE trial)</b>		<b>NEW ALBUMIN CONTAINER: Albutein FlexBag™</b>
 Pulmonology		<b>NON-CYSTIC FIBROSIS BRONCHIECTASIS: Alpha<sub>1</sub>-antitrypsin (AAT)</b>		<b>ALPHA<sub>1</sub>-ANTITRYPSIN DEFICIENCY: AAT 15% (subcutaneous)</b>		<b>ALPHA<sub>1</sub>-ANTITRYPSIN DEFICIENCY: Prolastin-C® Europe (SPARTA trial)</b>	<b>ALPHA<sub>1</sub>-ANTITRYPSIN DEFICIENCY: Prolastin® EU 4-5gr vials</b>
 Hematology	+		<b>SEPSIS: Antithrombin-III (AT-III)*</b>		<b>CONGENITAL DEFICIENCY &amp; SEVERE HYPOFIBRINOGEN: Fibrinogen</b>  <b>ACQUIRED FIBRINOGEN DEFICIENCY: Fibrinogen</b>	<b>CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) [REFRACTORY PATIENTS]: Fostamatinib**</b>  <b>ITP: Yimmugo® (IVIG-G Next Gen)</b> <small>Commercialization started</small>	
 Neurology	+++	<b>CADASIL AKST1220</b>  <i>CADASIL: Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy</i>		<b>ALZHEIMER'S DISEASE: GRF6019</b> <b>PARKINSON'S DISEASE WITH DEMENTIA: GRF6021</b>  <b>ALZHEIMER'S DISEASE: ABvac40</b> <b>PARKINSON'S DISEASE: AKST4290</b>			
 Infectious Diseases	+++	<b>HEPATITIS B INFECTION: GIGA 2339 (Recombinant hyperimmune Ig)</b>			<b>SEVERE COMMUNITY-ACQUIRED PNEUMONIA (SCAP): Trimodulin (IG-M)</b>  <b>HUMAN CYTOMEGALOVIRUS (CMV) INFECTION: Cytotec® Pregnancy (Polyclonal anti-CMV immunoglobulins)</b>		
 Further Therapeutic Opportunities	++	<b>CANCER: GIGA 564 (Anti-CTLA-4 mAb)</b>	<b>DRY EYE DISEASE: OSIG (Ocular surface immunoglobulin)***</b>	<b>nAMD and DR: AKST4290</b>  <b>END STAGE RENAL DISEASE: AKST1210</b>  <i>nAMD: Neovascular age-related macular degeneration DR: diabetic retinopathy</i>		<b>VARIOUS HEMATOLOGIC AND WOUND-HEALING INDICATIONS: VistaSeal™/VeraSeal™ (Fibrin Sealant) Biosurgery Pediatric Use</b>	

COLOR KEY AND NOTES

Plasma projects  
Non-plasma projects  
Biotest Collaborations

\*Partnership with Endpoint Health; \*\* Licensed rights from Rigel Pharmaceuticals in EU and other countries; \*\*\*Global collaboration and licensing agreement with Selagine, Inc.